Tilly Bingham
Tilly Bingham
GIO Therapeutics, Basel, Switzerland
Chief Scientific Officer/Chief Operating Officer
Tilly Bingham is a drug discoverer with >20 years’ experience of working in the pharmaceutical R&D sector in ‘large pharma’ (Organon, Schering-Plough, MSD), Biotech (Redx Pharma), CRO (Concept Life Sciences) and is currently CSO/COO at GIO Therapeutics and Executive in Residence at Cumulus Oncology.
Tilly’s early career was spent working as a medicinal chemist in CNS therapeutic areas where her research focussed on design strategies for getting small molecule therapeutics across the blood brain barrier for targets including the GPCRs OX2R, V1R and CGRP. Then, as Head of Research and Operations at Redx Pharma she oversaw the discovery and development of oncology and fibrosis clinical candidates, including the clinical candidate porcupine inhibitors RXC004 (oncology), RXC006 (fibrosis,/AZD5055), Pan RAF inhibitor (JZP815) and FDA approved BTK inhibitor (Pirtobrutinib /Jaypirca®).
Tilly is a member of the EFMC executive committee (European Federation of Medicinal Chemistry and Chemical Biology), an elected member of the Royal Society of Chemistry Organic Chemistry Community and is is co-editor of Progress in Medicinal Chemistry.
